Boston-based Xenomics is a private biotechnology company that is advancing breakthroughs in genetics and biomanufacturing to combat major sustainability issues in food, energy, and health. At the heart of its technology is a next generation multi-site gene editing platform that enables biological advancement on an unparalleled scale. Xenomics combines genomics, synthetic biology, computational biology, and nanotechnology to advance the science needed to address humanity's most complex sustainability challenges—feeding, fueling, and healing society.
Xenomics’ team is working to build an unparalleled portfolio of gene-editing technologies designed to scalably modify cellular DNA with previously unattainable precision and sophistication. Its Harvard and MIT trained executive team includes leading global scientists with subspecialties in molecular biology, computational biology, data science, AI/ML, materials science, nanotechnology, nanofabrication, and engineering. In recent years, several technologies have attempted to address the challenges of creating large-scale genome engineering. Xenomics’ novel approach to single-cell genome engineering interfaces with the best of traditional benchtop molecular biology tools and existing infrastructure. By creating a model that dramatically reduces capital requirements and by leveraging high performance computing partnerships and talent, Xenomics’ technology has immense economic and technical advantages over existing approaches.